Inogen(INGN) ZACKS·2025-02-26 17:10Core Insights - Inogen, Inc. reported a narrower adjusted loss per share of 24 cents for Q4 2024, compared to 83 cents in the same quarter last year and better than the Zacks Consensus Estimate of a 57 cents loss [1] - The company achieved revenues of $80.1 million for Q4 2024, reflecting a 5.5% year-over-year increase and surpassing the Zacks Consensus Estimate by 0.7% [2] Financial Performance - For the full year 2024, Inogen's total revenues reached $335.7 million, up 6.4% from 2023, with an adjusted loss per share of 86 cents, an improvement from the $2.08 loss per share in 2023 [4] - Adjusted gross profit for Q4 2024 increased by 25.4% to $39.3 million, with an adjusted gross margin expansion of 777 basis points to 49.1% [8] - Total operating expenses decreased by 16.6% year-over-year to $47.7 million, with adjusted operating loss narrowing to $8.3 million from $25.8 million in the prior year [9] Revenue Breakdown - Rental revenues for Q4 2024 were $13.8 million, down 16.5% year-over-year, while sales revenues increased by 11.6% to $66.3 million [5] - Domestic business-to-business sales rose 24.1% year-over-year to $22.4 million, and international business-to-business sales increased by 31.5% to $28.3 million [6] Guidance and Outlook - For Q1 2025, Inogen expects revenues between $79 million and $81 million, indicating growth of 1-4% from Q1 2024 [11] - For the full year 2025, the revenue outlook is set between $352 million and $355 million, reflecting a growth of 5-6% from 2024 [12] Strategic Developments - Inogen entered a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., aimed at expanding its product portfolio and enhancing its innovation pipeline [14]